Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
2018/09/05 by Damian Stichel, Azadeh Ebrahimi, David Reuß +16 · 312 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Anaplastic astrocytoma #Astrocytoma #Biology #Cancer research #Chromatin Remodeling and Cancer #Chromosome #Chromosome 7 (human) #Gene #Genetics #Glioma #Glioma Diagnosis and Treatment #Medicine #MicroRNA in disease regulation #Mutation #Pathology #Surrogate endpoint
paper · doi:10.1007/s00401-018-1905-0
published in Acta Neuropathologica 136(5), 793-803 (Springer Science+Business Media)
openalex publication_date 2018/09/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05
Abstract
EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chromosome 10 (7+/10-), and TERT promoter mutation (pTERTmut) are alterations frequently observed in adult IDH-wild-type (IDHwt) glioblastoma (GBM). In the absence of endothelial proliferation and/or necrosis, these alterations currently are considered to serve as a surrogate for upgrading IDHwt diffuse or anaplastic astrocytoma to GBM. Here, we set out to determine the distribution of EGFRamp, 7+/10-, and pTERTmut by analyzing high-resolution copy-number profiles and next-generation sequencing data of primary brain tumors. In addition, we addressed the question whether combinations of partial gains on chromosome 7 and partial losses on chromosome 10 exhibited a diagnostic and prognostic value similar to that of complete 7+/10-. Several such combinations proved relevant and were combined as the 7/10 signature. Our results demonstrate that EGFRamp and the 7/10 signature are closely associated with IDHwt GBM. In contrast, pTERTmut is less specific for IDHwt GBM. We conclude that, in the absence of endothelial proliferation and/or necrosis, the detection of EGFRamp is a very strong surrogate marker for the diagnosis of GBM in IDHwt diffuse astrocytic tumors. The 7/10 signature is also a strong surrogate marker. However, care should be taken to exclude pleomorphic xanthoastrocytoma. pTERTmut is less restricted to this entity and needs companion analysis by other molecular markers to serve as a surrogate for diagnosing IDHwt GBM. A combination of any two of EGFRamp, the 7/10 signature and pTERTmut, is highly specific for IDHwt GBM and the combination of all three alterations is frequent and exclusively seen in IDHwt GBM.
Cited by
- +7/−10 chromosome copy-number alteration in the elderly: A cautionary tale from 2 cases
- Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
- Comparison of Fluorescence In Situ Hybridization, Next-Generation Sequencing, and DNA Methylation Microarray for Copy Number Variation Assessment in Gliomas
- cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors
- Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a “molecular” glioblastoma
- cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". [europepmc]
- Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. [europepmc]
- Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. [europepmc]
- Total copy number variation as a prognostic factor in adult astrocytoma subtypes. [europepmc]
- Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis. [europepmc]
- Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. [europepmc]
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. [europepmc]
- Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. [europepmc]
- Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. [europepmc]
- Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. [europepmc]
- Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. [europepmc]
- Clinical Management of Diffuse Low-Grade Gliomas. [europepmc]
- Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. [europepmc]
- MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas. [europepmc]
- Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. [europepmc]
- Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. [europepmc]
- Prognostic and Predictive Biomarkers in Gliomas. [europepmc]
- Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. [europepmc]
- Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. [europepmc]
- Molecular and Circulating Biomarkers in Patients with Glioblastoma. [europepmc]
- Adult type diffuse gliomas in the new 2021 WHO Classification. [europepmc]
- Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects. [europepmc]
- Glioblastoma Therapy: Past, Present and Future. [europepmc]
- Principles in the Management of Glioblastoma. [europepmc]
- Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches. [europepmc]
Related